secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0001100682-25-000009
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Labs Q4 GAAP loss $(4.22) on $215M goodwill impairment; guides FY2025 revenue down 5.5-3.5%
--------------------------------------------------------------------------------

- Q4 revenue $1.00B (-1.1% YoY); non-GAAP EPS $2.66 (+8.1%); GAAP loss $(4.22) from $215M Biologics Solutions goodwill impairment.
- Full-year 2024 revenue $4.05B (-1.9%); non-GAAP EPS $10.32 (-3.3%); GAAP EPS $0.20 (-97.8%).
- DSA segment revenue down 3.6% organically; Manufacturing organic +2.1%; RMS organic -0.4% despite Noveprim acquisition.
- 2025 guidance: organic revenue decline 5.5% to 3.5%; non-GAAP EPS $9.10-$9.60; plans $350M stock repurchase.
- CEO cites ongoing biopharma client restructuring; expects stable-to-slightly improved biotech demand in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/0001100682-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068225000009/crl-20250219.htm
  HTML page:      https://secwatch.observer/filing/0001100682-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer